Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (otvara novi prozor)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Izvor‎: Hemoglobin 2014;38(1):44-8.

Indeks‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (otvara novi prozor)

Hydroxyurea in thalassemia intermedia--a promising therapy. (otvara novi prozor)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Izvor‎: Ann Hematol 2005;84(7):441-6.

Indeks‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (otvara novi prozor)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (otvara novi prozor)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Izvor‎: J Clin Pathol 2010;63(2):147-50.

Indeks‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (otvara novi prozor)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (otvara novi prozor)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Izvor‎: Eur J Haematol 2009;82(3):213-8.

Indeks‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (otvara novi prozor)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (otvara novi prozor)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Izvor‎: Eur J Haematol 2010;84(1):52-8.

Indeks‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (otvara novi prozor)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (otvara novi prozor)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Izvor‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indeks‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (otvara novi prozor)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (otvara novi prozor)

Perrine SP.

Izvor‎: Pediatr Ann 2008;37(5):339-46.

Indeks‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (otvara novi prozor)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (otvara novi prozor)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Izvor‎: Ann N Y Acad Sci 2005;1054:250-6.

Indeks‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (otvara novi prozor)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (otvara novi prozor)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Izvor‎: Acta Haematol 2004;111(4):189-95.

Indeks‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (otvara novi prozor)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (otvara novi prozor)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Izvor‎: Blood Purif 2004;22(5):453-60.

Indeks‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (otvara novi prozor)

The role of recombinant human erythropoietin in the treatment of thalassemia. (otvara novi prozor)

Rachmilewitz EA, Aker M.

Izvor‎: Ann N Y Acad Sci 1998;850:129-38.

Indeks‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (otvara novi prozor)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (otvara novi prozor)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Izvor‎: Br J Haematol 2011;154(2):281-4.

Indeks‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (otvara novi prozor)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (otvara novi prozor)

Thein SL.

Izvor‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indeks‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (otvara novi prozor)